Table II.

Copeptin in prediction of combined end point and its components in individuals with or without diabetes

	Diabetic cases						Nondiabetic cases
	n total/n event	HR (95% CI)	P⁎	P†	P‡	P§	n total/n event	HR (95% CI)	P⁎
Primary end point (CAD + death + HF)║	895/287	1.32 (1.10-1.58)	.003	.02	.02	.002	4187/845	1.01 (0.95-1.09)	.70
CAD ¶	895/164	1.33 (1.04-1.69)	.02	.048	.053	.03	4187/319	1.02 (0.90-1.15)	.78
HF#	895/58	1.62 (1.09-2.41)	.02	.04	.04	.02	4187/95	1.22 (0.94-1.58)	.13
Death ║	895/165	1.32 (1.04-1.68)	.02	.13	.17	.01	4187/599	1.00 (0.92-1.08)	.92

HRs are expressed as per SD increment of ln-transformed copeptin.

^⁎Adjusted for age, sex, LDL, HDL, systolic blood pressure, antihypertensive treatment, and smoking (model 1).

^†Model adjusted for glucose on top of model 1 adjustment.

^‡Model adjusted for HbA1c on top of model 1 adjustment.

^§Model adjusted for Insulin on top of model 1 adjustment.

^║Model adjusted for prevalent CAD and prevalent HF on top of model 1 adjustment.

^¶Model adjusted for prevalent CAD on top of model 1 adjustment.

^#Model adjusted for prevalent HF on top of model 1 adjustment.